BRISTOL-MYERS SQUIBB COMPANY;UNIVERSITE DE MONTREAL
发明人:
BANVILLE, JACQUES,REMILLARD, ROGER,RUEDIGER, EDWARD H.,DEON, DANIEL H.,GAGNON, MARC,DUBE, LAURENCE,GUY, JULIA,PRIESTLEY, ELDON SCOTT,POSY, SHOSHANA L.,MAXWELL, BRAD D.,WONG, PANCRAS C.,LAWRENCE, R. MI
申请号：
PE2014001782
公开号：
PE20142285A1
申请日:
2013.04.24
申请国别(地区):
PE
年份:
2015
代理人:
摘要：
REFERS TO COMPOUNDS DERIVED FROM IMIDAZOTIADIAZOLE AND IMIDAZOPYRAZINE FROM FORMULA (I) WHERE W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X4 AND THE RING A ARE AS DEFINED HEREIN , OR A STEREOISOMER, A TAUTOMER OR A PHARMACEUTICALLY ACCEPTABLE SALT. THEY ARE PREFERRED COMPOUNDS: 2-METOXI-6- (6-METOXI-4 - (((2- (TRIFLUOROMETIL) TIAZOL-4-IL) METOXI) BENZOFURAN-2-IL) IMIDAZO [2,1-b] [1,3 , 4] TIADIAZOLE； 2-METOXI-6- (6-METOXI-4 - ((2-PHENYLTIAZOL-4-IL) METOXI) BENZOFURAN-2-IL) IMIDAZO [2,1-b] [1,3,4] TIADIAZOL；There are others He also mentioned a pharmaceutical composer These compounds are receptor antagonists triggered by class 4 proteome (PAR4), which inhibit platelet polymer as an effective means to treat or prevent thrombotic disorders.SE REFIERE A COMPUESTOS DERIVADOS DE IMIDAZOTIADIAZOL E IMIDAZOPIRAZINA DE LA FORMULA (I) DONDE W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3, X4 Y EL ANILLO A SON COMO SE DEFINEN EN LA PRESENTE, O UN ESTEREOISOMERO, UN TAUTOMERO O UNA SAL FARMACEUTICAMENTE ACEPTABLE. SON COMPUESTOS PREFERIDOS: 2-METOXI-6-(6-METOXI-4-((2-(TRIFLUOROMETIL)TIAZOL-4-IL)METOXI)BENZOFURAN-2-IL)IMIDAZO[2,1-b][1,3,4]TIADIAZOL； 2-METOXI-6-(6-METOXI-4-((2-FENILTIAZOL-4-IL)METOXI)BENZOFURAN-2-IL)IMIDAZO[2,1-b][1,3,4]TIADIAZOL； ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR ACTIVADO POR PROTEASA TIPO 4 (PAR4) QUE INHIBEN LA AGREGACION PLAQUETARIA SIENDO UTILES PARA TRATAR O PREVENIR TRASTORNOS TROMBOEMBOLICOS
